Raydiant Oximetry, a Mountain View, California developer of noninvasive technology that directly monitors a babies’ oxygenation during pregnancy, raised $1m in seed funding.
The round was led by AngelMD.
Founded in 2016 and led by CEO Dr. Neil P. Ray, Raydiant Oximetry is a medical device company that has developed a novel fetal monitor to improve patient outcomes for both mothers and babies during childbirth. Raydiant Oximetry is currently in residence at the Fogarty Institute for Innovation in Mountain View, California.
The company has demonstrated feasibility of the technology in pregnant women through an IRB-approved study and validated the results through animal models. It holds two issued patents protecting the core technology, and expects up to ten more patents over the next 36 months.
Raydiant intends to use the funds to build a subsequent prototype with improved accuracy and reliability.